Expanded Access Program – Ulixertinib

xCures partnered with BioMed Valley Discoveries to offer expanded access to ulixertinib, a first-in-class ERK1/2 inhibitor, for patients with advanced solid tumors who are no longer responding to or have exhausted standard of care. Detailed inclusion/exclusion criteria can be found at clinicaltrials.gov.